Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Compared to the effect of placebo, it improved both progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Guoshuang, Zheng, Fangchao, Ren, Dengfeng, Du, Feng, Dong, Qiuxia, Wang, Ziyi, Zhao, Fuxing, Ahmad, Raees, Zhao, Jiuda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146601/
https://www.ncbi.nlm.nih.gov/pubmed/30231931
http://dx.doi.org/10.1186/s13045-018-0664-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146601/
https://www.ncbi.nlm.nih.gov/pubmed/30231931
http://dx.doi.org/10.1186/s13045-018-0664-7

Ejemplares similares